Related Experiment Videos
Interleukin 5 as a drug target in allergy and asthma
Trends in Pharmacological Sciences
|February 1, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Inhibition of diabetes in NOD mice by human pregnancy factor.
Human immunology·2002
CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model.
American journal of respiratory cell and molecular biology·2001
1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.
Journal of immunology (Baltimore, Md. : 1950)·2001
Apocynin and 1400 W prevents airway hyperresponsiveness during allergic reactions in mice.
British journal of pharmacology·2001
Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2001
De-Nterm-ining GLP1R signaling bias.
Trends in pharmacological sciences·2026
Trojan mast cells: repurposing allergy for targeted oncolytic delivery.
Trends in pharmacological sciences·2026
Tau-targeting pharmacological strategies in neurodegenerative disease.
Trends in pharmacological sciences·2026
Sequential EGFR inhibition sensitizes glioblastoma to temozolomide.
Trends in pharmacological sciences·2026
Reprogramming pain signaling through photopharmacology.
Trends in pharmacological sciences·2026
Lysosome-targeted protein degradation platforms for spatiotemporally controlled degradation.
Trends in pharmacological sciences·2026
The impact of anxiety on vulvar dermatological diseases: a systematic review.
International journal of women's dermatology·2026
In vitro diagnostics in hymenoptera venom allergy: Current concepts and perspectives.
Allergologie select·2026
CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.
Molecular therapy. Advances·2026
Unraveling the Pathogenetic Potential and Immune Crosstalk of Yersinia spp. in Inflammatory Bowel Disease.
Journal of immunology research·2026